Prostatype Genomics AB (OSTO:PROGEN) Shares Buyback Ratio %: -59.97 (As of Sep. 02, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OSTO:PROGEN Prostatype Genomics AB OSTO:PROGEN
16 GF Score
Price kr0.14
GF Value kr0.15
Valuation Fairly Valued
! 6 Warning Signs
View Full Analysis

What is Prostatype Genomics AB Shares Buyback Ratio %?

Prostatype Genomics AB OSTO:PROGEN +2.52% 16 Shares Buyback Ratio % is -59.97 as of Sep. 02, 2026. GuruFocus rates OSTO:PROGEN with a GF Score™ of 16/100 and a GF Value™ of kr0.15 (Fairly Valued). The stock has 6 warning signs investors should review.

Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.

GuruFocus calculates shares buyback ratio using previous shares outstanding minus the current shares outstanding, and then divides by previous shares outstanding. Prostatype Genomics AB's current shares buyback ratio was -59.97%.

Prostatype Genomics AB Shares Buyback Ratio % Related Terms

Prostatype Genomics AB Shares Buyback Ratio % Historical Data

* Premium members only.

The historical data trend for Prostatype Genomics AB's Shares Buyback Ratio % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Prostatype Genomics AB Shares Buyback Ratio % Chart

Prostatype Genomics AB Annual Data
Trend Jun18 Jun19 Dec21 Dec22 Dec23 Dec24 Dec25
Shares Buyback Ratio %
Get a 7-Day Free Trial -62.05 -51.52 -73.82 -1,600.89 -378.36

Prostatype Genomics AB Semi-Annual Data
Jun18 Jun19 Jun20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
Shares Buyback Ratio % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -435.15 -217.84 -199.03 -59.97 0.00
OSTO:PROGEN
16GF Score
Prostatype Genomics AB OSTO:PROGEN
Shares Buyback Ratio % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Prostatype Genomics AB Shares Buyback Ratio % Calculation

Prostatype Genomics AB's Shares Buyback Ratio for the fiscal year that ended in Dec. 2025 is calculated as

Shares Buyback Ratio=(Shares Outstanding (EOP) (A: Dec. 2024 ) - Shares Outstanding (EOP) (A: Dec. 2025 )) / Shares Outstanding (EOP) (A: Dec. 2024 )
=(32.521 - 155.568) / 32.521
=-378.36%

Prostatype Genomics AB's Shares Buyback Ratio for the quarter that ended in Jun. 2026 is calculated as

Shares Buyback Ratio=(Shares Outstanding (EOP) (A: Dec. 2025 ) - Shares Outstanding (EOP) (A: Jun. 2026 )) / Shares Outstanding (EOP) (A: Dec. 2025 )
=(155.568 - 155.568) / 155.568
=0.00%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Shares Buyback Ratio % →
What does a Shares Buyback Ratio % of -59.97 mean?
Prostatype Genomics AB (OSTO:PROGEN) has a Shares Buyback Ratio % of -59.97 as of Sep. 02, 2026. Share buyback ratio is the percent change of a company's shares outstanding from two periods. View historical data on Prostatype Genomics AB and its competitors.
Is Prostatype Genomics AB's Shares Buyback Ratio % too high?
Prostatype Genomics AB's current Shares Buyback Ratio % is -59.97. Overall, Prostatype Genomics AB has a GF Score™ of 16/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Prostatype Genomics AB's Shares Buyback Ratio % compare to TMO and DHR?
Prostatype Genomics AB's Shares Buyback Ratio % of -59.97 can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shares Buyback Ratio % for a Medical Diagnostics & Research company?
A good Shares Buyback Ratio % depends on the Medical Diagnostics & Research industry context. However, Shares Buyback Ratio % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shares Buyback Ratio % mean?
A high Shares Buyback Ratio % can signal that a stock is expensive relative to its fundamentals. Share buyback ratio is the percent change of a company's shares outstanding from two periods. View historical data on Prostatype Genomics AB and its competitors. Prostatype Genomics AB's current Shares Buyback Ratio % is -59.97. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Prostatype Genomics AB stock overvalued right now?
Based on GuruFocus' analysis, Prostatype Genomics AB (OSTO:PROGEN) is currently considered Fairly Valued. The stock's GF Value™ is kr0.15, compared to a current price of kr0.14 — trading 5% below its estimated fair value. The current Shares Buyback Ratio % is -59.97. Prostatype Genomics AB's overall GF Score™ is 16/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shares Buyback Ratio % calculated?
Shares Buyback Ratio % is calculated from a company's financial statements. For Prostatype Genomics AB (OSTO:PROGEN), the current Shares Buyback Ratio % is -59.97 as of Sep. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Prostatype Genomics AB (OSTO:PROGEN) Overvalued in 2026?

Based on GuruFocus' analysis, Prostatype Genomics AB stock appears to be undervalued. The current stock price of kr0.14 is trading 5% below its estimated GF Value™ of kr0.15. GuruFocus considers Prostatype Genomics AB to be Fairly Valued.

Key valuation signals for OSTO:PROGEN:

  • Shares Buyback Ratio %: -59.97
  • GF Value™: kr0.15 vs. price of kr0.14 (5% below fair value)
  • GF Score™: 16/100 with 6 warning signs

No single metric tells the full story. See the OSTO:PROGEN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Prostatype Genomics AB Business Description

Other Exchanges PGO0:Germany
Address Augustendalsvagen 20, Nacka Strand, SWE, 131 52
Prostatype Genomics AB manufactures, markets and sells the prognostic gene test Prostatype. By assessing the aggressiveness of prostate cancer, Prostatype helps clinicians and patients to make correct treatment decisions. Over and under treatment of prostate cancer can be minimized, the quality of life for the patient improved and money can be saved for the health care sector.
16GF Score

Get the complete analysis for OSTO:PROGEN

Shares Buyback Ratio % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr0.14
Price
kr0.15
GF Value